Evidence map›Paper›PMID 34711000›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.

Noura Fathy El-Metwaly, Salah Aref, Mohamed Ayed, Manal Abdel Hamid, Ahmed M A El-Sokkary

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Molecular therapy. Nucleic acids · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Noura Fathy El-MetwalyBiochemistry Subdivision, Department of Chemistry, Faculty of Science; Mansoura University, Mansoura, Egypt.
Salah ArefHematology Unit, Department of Clinical Pathology, Mansoura University, Mansoura, Egypt.ORCID 0000-0002-4822-5204
Mohamed AyedHematology Unit, Department of Clinical Pathology, Mansoura University, Mansoura, Egypt.
Manal Abdel HamidDepartment of Medical Oncology, Mansoura University Oncology Center (MUOC), Mansoura, Egypt.
Ahmed M A El-SokkaryBiochemistry Subdivision, Department of Chemistry, Faculty of Science; Mansoura University, Mansoura, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current predictor of the Chronic myeloid leukemia (CML)  patients' outcome is the degree of response to targeted therapy; here we search for a biomarker predicting CML outcome before start of therapy. This study aimed to assess the impact of the  CD34+/CD38- stem cells (SCs) burden in chronic myeloid leukemia (CML) on  treatment response and patients' outcomes.

methodsOur study included 65 CML patients in the chronic phase. The patients'  CD34+/CD38- stem cells were quantified  using flowcytometry before and after treatment by frontline imatinib (IM) therapy. The median follow-up for all patients was 18 months.

resultsCD34+/CD38- stem cells frequency at diagnosis and after therapies are correlated to known prognostic markers (blast cells count, spleen size, total White cell count, and clinical scores). After therapy, the leukemic stem cells count dropped rapidly. The pretreatment CD34+/CD38- stem cells burden predicts response to frontline therapy. In addition, high SCs frequency at diagnosis predicts poor molecular response, transformation to AML, and poor patients' outcomes.

conclusionThe percentage of CD34+/CD38- SCs burden at diagnosis reflects the CML disease behavior and is considered a biomarker for predicting CML patients' response to first-line Tyrosine kinase inhibitors (TKI) therapy.

Indexed as

ADP-ribosyl Cyclase 1Antigens, CD34AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCell Transformation, NeoplasticDrug Resistance, NeoplasmFemaleFlow CytometryHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteADP-ribosyl Cyclase 1Antigens, CD34Antineoplastic AgentsBiomarkers, TumorImatinib MesylateProtein Kinase InhibitorsCMLoutcomestem cells

Identifiers

PMID34711000
PMCPMC8858256
OpenAlexW3209382449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.